Navigation Links
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014
Date:7/31/2014

ent of metastatic breast cancer and is also in Phase 2 studies for the treatment of lung and brain cancers. In anti-infectives, Amikacin Inhale is in Phase 3 studies conducted by Bayer Healthcare as an adjunctive treatment for intubated and mechanically ventilated patients with Gram-negative pneumonia. Additional late-stage development products that leverage Nektar's proprietary technology platform include Baxter's BAX 855, a longer-acting rFVIII program, which is in Phase 3 clinical development for patients with hemophilia A.

Nektar's technology has enabled eight approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.

Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com

*Sources: Bell TJ et. al. Pain Med 2009;10(1):35-42, Hess B et. al. Eur J Intern Med 2011;22(5):527-531, Rosti G et. al Eur Rev Med Pharmacol Sci. 2010;14(12):1045-1050. Galvez R et. al. Aten Primaria 2014;46(1):32-39, Droney J et. al. Support Care Cancer 2008;16(5):453-459.

Movantik is a trademark of AstraZeneca.

Cautionary Note Regarding Forward-Looking StatementsThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the potential regulatory approval of Movantik&
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets
2. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA
3. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
4. Nektar to Announce Financial Results for the Third Quarter of 2013 on Thursday, November 7, 2013, After Close of U.S.-Based Financial Markets
5. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
6. Nektar Therapeutics Reports Financial Results for the Second Quarter of 2013
7. Nektar to Announce Financial Results for the Second Quarter of 2013 on Thursday, August 8, 2013, After Close of U.S.-Based Financial Markets
8. Nektar Completes Enrollment in Phase 3 BEACON Study of Etirinotecan Pegol in Women With Metastatic Breast Cancer
9. Nektar Therapeutics Presents Positive Data from Human Abuse Liability Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2013 Annual Meeting of The College on Problems of Drug Dependence
10. Nektar Presents Positive Preclinical Data for NKTR-214, a Novel Cancer Immunotherapy, At the 2013 American Society of Clinical Oncology Annual Meeting
11. Nektar Presents Target-Specific Biomarkers Being Assessed in Ongoing Phase 3 BEACON Study of Etirinotecan Pegol for the Treatment of Metastatic Breast Cancer at the 2013 American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... Ill., Oct. 31, 2014  AbbVie (NYSE: ... the third quarter ended Sept. 30, 2014. ... performance of our business with double-digit growth from ... business grew nearly 14 percent in the quarter ... chief executive officer, AbbVie.  "We exceeded our outlook ...
(Date:10/30/2014)... 2014 Stryker Orthopaedics, the Official Joint Replacement ... rounding out its debut year of the relationship at ... AZ. This marks the eleventh tournament stop ... the brand has activated on-site with the "Stryker Mobility ... on the importance of joint health.  ...
(Date:10/30/2014)...  Zimmer Holdings, Inc. (NYSE: ZMH ... team and organizational structure of the combined company following ... that the combined organization will leverage the strength of ... with the new brand to be rolled out across ... The future leadership team is committed to establishing Zimmer ...
Breaking Medicine Technology:AbbVie Reports Third-Quarter 2014 Financial Results 2AbbVie Reports Third-Quarter 2014 Financial Results 3AbbVie Reports Third-Quarter 2014 Financial Results 4AbbVie Reports Third-Quarter 2014 Financial Results 5AbbVie Reports Third-Quarter 2014 Financial Results 6AbbVie Reports Third-Quarter 2014 Financial Results 7AbbVie Reports Third-Quarter 2014 Financial Results 8AbbVie Reports Third-Quarter 2014 Financial Results 9AbbVie Reports Third-Quarter 2014 Financial Results 10AbbVie Reports Third-Quarter 2014 Financial Results 11AbbVie Reports Third-Quarter 2014 Financial Results 12AbbVie Reports Third-Quarter 2014 Financial Results 13AbbVie Reports Third-Quarter 2014 Financial Results 14AbbVie Reports Third-Quarter 2014 Financial Results 15AbbVie Reports Third-Quarter 2014 Financial Results 16AbbVie Reports Third-Quarter 2014 Financial Results 17AbbVie Reports Third-Quarter 2014 Financial Results 18AbbVie Reports Third-Quarter 2014 Financial Results 19AbbVie Reports Third-Quarter 2014 Financial Results 20AbbVie Reports Third-Quarter 2014 Financial Results 21AbbVie Reports Third-Quarter 2014 Financial Results 22AbbVie Reports Third-Quarter 2014 Financial Results 23AbbVie Reports Third-Quarter 2014 Financial Results 24Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 2Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 3Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 4Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 2Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 3Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 4Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 5Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 6Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 7Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 8Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 9
... Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing ... autoimmune diseases, today announced that its Senior Vice President and ... Annual BIO Investor Forum on October 29, 2009 in San ... available on the company,s website at www.micromet-inc.com ...
... Incorporated (Nasdaq: ARAY ), a global leader in ... an America,s region thereby establishing regionalized management and operational ... formation of this new Americas region, along with the ... each region control of revenue and profitability and responsibility ...
Cached Medicine Technology:Micromet to Present at The 8th Annual BIO Investor Forum Conference on October 29, 2009 2Accuray Announces Regionalized Management Strategy for Americas 2Accuray Announces Regionalized Management Strategy for Americas 3
(Date:10/31/2014)... combination that can trigger the self-destruct process in lung ... according to research that will be presented at the ... next week*. , When healthy cells are no longer ... self destruction. But cancer cells swerve away from this ... grow out of control – causing tumours to form. ...
(Date:10/31/2014)... York, NY (PRWEB) October 31, 2014 ... one of the most remarkable gifts of life — ... platform for matching extraordinary surrogate mothers and donors with ... about individuals in unforeseen circumstances. , It’s a collective ... donors, surrogacy agencies, surrogacy lawyers, and fertility clinics that ...
(Date:10/31/2014)... Triple Board Certified surgeon Dr. Jeffrey ... transform the appearance of military veteran Joseph Jones. ... Plastic and Reconstruction Surgery (AAFPRS) Faces of Honor program, ... hair Jones lost during an IED blast almost ten ... procedure, valued around $16,000, took Dr. Epstein over eight ...
(Date:10/31/2014)... October 31, 2014 BCC Research ( http://www.bccresearch.com ... AIR QUALITY MARKET , the U.S. indoor air quality (IAQ) ... with a compound annual growth rate (CAGR) of 7% over ... to grow at a CAGR of 7.4%. , Since ... toxic mold, the outbreak of infectious diseases such as bird ...
(Date:10/31/2014)... 2014 Radiology and EMR Integration ... difference between diagnostic imaging centers but Connectivity is ... DigitalOne. “Differentiation is critical in all businesses ... you consider the intense competition and the downward ... will stand-out from the competition by fully integrating ...
Breaking Medicine News(10 mins):Health News:Scientists trigger self-destruct switch in lung cancer cells 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 2Health News:Over 800 New Surrogate Mother Members at FindSurrogateMother.com Helping Create Pathways to Parenthood 3Health News:Miami Hair Restoration Specialist Transforms Wounded Soldier 2Health News:Global Market for U.S. Indoor Air Quality (IAQ) to Reach $11.4 Billion by 2019; Equipment Market Segment Surging at 7.4% CAGR 2Health News:Global Market for U.S. Indoor Air Quality (IAQ) to Reach $11.4 Billion by 2019; Equipment Market Segment Surging at 7.4% CAGR 3Health News:Diagnostic Imaging of Salem Expects Growth Partnering with DigitalOne 2
... HLS ) announced today that its Board of Directors ... on its 6.5%,Series A Convertible Perpetual Preferred Stock, payable ... 2, 2008., About HealthSouth, HealthSouth is the ... states across the country and in,Puerto Rico, HealthSouth serves ...
... (Dec. 20, 2007) -- Using new approaches, an interdisciplinary ... in New York City has gained a view of ... difficulty in patients with borderline personality disorder -- shedding ... early days yet, but the work is pinpointing functional ...
... More Benefit Online Nurse Community, SAN DIEGO, ... professionals to connect with their peers are growing ... site rising to the top,designed exclusively for nursing ... with their peers. NurseConnect, (http://www.nurseconnect.com ) is a ...
... 21 Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ) ... application (sNDA) with the U.S. Food and Drug,Administration ... with,previously untreated multiple myeloma (MM). The filing is ... VISTA(1) trial, one of the largest,international, randomized clinical ...
... MURRYSVILLE, Pa., Dec. 21 RESPIRONICS, INC.,(Nasdaq: RESP ... merger,agreement pursuant to which Royal Philips Electronics (AEX: PHI, ... all of the outstanding,shares of Respironics for USD 66.00 ... approximately USD 5.1 billion. The offer price represents a,premium ...
... Upon an ex parte motion,by the Service Employees ... (TRO) was issued late on Thursday, December 20,by ... Michigan,enjoining the Michigan Department of Community Health, Manor ... Group from taking certain actions related to,completing the ...
Cached Medicine News:Health News:HealthSouth Declares Dividend on 6.5% Series A Convertible Perpetual Preferred Stock 2Health News:Scientists identify brain abnormalities underlying key element of borderline personality disorder 2Health News:Scientists identify brain abnormalities underlying key element of borderline personality disorder 3Health News:Scientists identify brain abnormalities underlying key element of borderline personality disorder 4Health News:Professional Networking Web Site, NurseConnect.com Launches Innovative Features 2Health News:Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma 2Health News:Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma 3Health News:Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma 4Health News:Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma 5Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 2Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 3Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 4Health News:Royal Philips Electronics to Acquire Respironics for USD $66.00 Per Share 5Health News:Manor Care To Vigorously Contest TRO 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: